Inflammation
Conditions
Keywords
SGLT2 inhibitors, Dapagliflozin, Inflammation
Brief summary
The research aims to understand how a specific type of medication called Sodium-glucose co-transporter 2 (SGLT2) inhibitors affect cardiorenal inflammation.
Interventions
Participants will receive 10mg of Dapagliflozin per day for three days.
Sponsors
Washington University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age: ≥18 * Patient has no prior history or use of Sodium-Glucose Co-transporter 2 Inhibitors. * Women who are surgically sterilized, amenorrheic for a year, on long-term contraceptives like intrauterine devices and implantable and injectable contraceptives. * Willing and able to complete the outcome assessments.
Exclusion criteria
* History of cardiac diseases (Heart Failure, NSTEMI/STEMI, cardiomyopathies, myocarditis). * Diagnosis of Type I Diabetes Mellitus. * Symptomatic hypotension (symptoms of hypotension + Systolic blood pressure \< 90). * Estimated glomerular filtration rate \<25 mL/minute/1.73 m2, with renal function test done within a year from the study enrollment date. * Alcohol use disorder as defined by the NIAAA or use of controlled substances or smoking cigarettes. * History of dapagliflozin or other Sodium-Glucose Co-transporter 2 Inhibitor sensitivity. * Other concomitant disease or condition that the investigator deems unsuitable for the study, including psychiatric, behavioral, or cognitive disorders, sufficient to interfere with the patient's ability to understand and comply with the study instructions or follow-up procedures. * Women who are pregnant or intend to become pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in the markers of Inflammation at three days | From enrollment to the end of treatment at 3 days. |
Countries
United States
Outcome results
None listed